Mostrar el registro sencillo del ítem
Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain
dc.contributor.author | Requena, S. | |
dc.contributor.author | Lozano, A. B. | |
dc.contributor.author | Caballero, Estrella | |
dc.contributor.author | García, F. | |
dc.contributor.author | Nieto, M. C. | |
dc.contributor.author | Tellez, R. | |
dc.contributor.author | ...et al. | |
dc.contributor.author | Soriano, Vicente | |
dc.date | 2019-05 | |
dc.date.accessioned | 2019-10-09T06:58:54Z | |
dc.date.available | 2019-10-09T06:58:54Z | |
dc.identifier.issn | 1460-2091 | |
dc.identifier.uri | https://reunir.unir.net/handle/123456789/9409 | |
dc.description.abstract | Background: HIV-2 is a neglected virus despite estimates of 1-2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2. Methods: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with integrase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modalities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed. Results: From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126 cells/mm(3), respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1). Conclusions: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individuals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Journal of Antimicrobial Chemotherapy | es_ES |
dc.relation.ispartofseries | ;vol. 74, nº 5 | |
dc.relation.uri | https://academic.oup.com/jac/article-abstract/74/5/1357/5315652?redirectedFrom=fulltext | es_ES |
dc.rights | restrictedAccess | es_ES |
dc.subject | JCR | es_ES |
dc.subject | Scopus | es_ES |
dc.title | Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain | es_ES |
dc.type | Articulo Revista Indexada | es_ES |
reunir.tag | ~ARI | es_ES |
dc.identifier.doi | https://doi.org/10.1093/jac/dkz007 |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |